|
1
|
Mutation of FOXL2 in granulosa-cell tumors of the ovary.
|
N Engl J Med
|
2009
|
5.63
|
|
2
|
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.
|
Oncogene
|
2005
|
1.89
|
|
3
|
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
|
Clin Cancer Res
|
2004
|
1.67
|
|
4
|
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
|
Cancer
|
2005
|
1.47
|
|
5
|
Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
|
Cancer Res
|
2006
|
1.47
|
|
6
|
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
|
Oncogene
|
2005
|
1.16
|
|
7
|
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
|
Breast Cancer Res
|
2005
|
1.08
|
|
8
|
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
|
Mod Pathol
|
2006
|
0.97
|
|
9
|
Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients.
|
Pathology
|
2008
|
0.87
|
|
10
|
A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations.
|
J Mol Diagn
|
2013
|
0.85
|
|
11
|
Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer.
|
Cancer Lett
|
2007
|
0.83
|
|
12
|
Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.
|
Clin Breast Cancer
|
2006
|
0.83
|